531 results about "Inflammatory cell" patented technology

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

The invention discloses a rhizoma smilacis glabrae leavening and a preparation method and application thereof in hyperuricemia, and the scheme is as follows: inoculating a lactobacillus fermentation seed solution into a rhizoma smilacis glabrae traditional Chinese medicine stock solution, fermenting for 48-72 hours at 37 DEG C, and freeze-drying to obtain the rhizoma smilacis glabrae leavening; the lactobacillus brevis fermentation seed liquid is prepared by fermenting lactobacillus brevis YM 1301 and lactobacillus plantarum CICC24202, and the lactobacillus brevis YM 1301 and the lactobacillus plantarum CICC24202 are fermented; the lactobacillus fermentation seed liquid accounts for 6-10% of the volume of the rhizoma smilacis glabrae traditional Chinese medicine Results show that after the rhizoma smilacis glabrae is fermented, the contents of total flavone and total polyphenol are increased, and the polysaccharide content is reduced; the rhizoma smilacis glabrae leavening can significantly reduce serum uric acid, urea nitrogen and creatinine levels of HUA rats; the kidney injury caused by hyperuricemia is improved; the increase of inflammatory cytokines such as IL-1beta and TNF-alpha in serum is reduced, and the curative effect is superior to that of unfermented rhizoma smilacis glabrae; the mechanism of reducing uric acid may be by inhibiting the activity of xanthine oxidase in HUA rats and increasing the excretion of uric acid in excrement. The invention provides a solid theoretical reference basis for developing safe and effective uric acid-reducing traditional Chinese medicine large-scale health products.

The invention belongs to the technical field of biological medicines, and particularly relates to a pyruvate preparation for treating asthma and a preparation method of the pyruvate preparation. The pyruvate preparation is prepared from the following components in parts by weight: 10 to 12 parts of pyruvate, 10 to 12 parts of sodium chloride, 0.5 to 1 part of citric acid and 500 parts of water for injection. The pH value of the pyruvate preparation is 6 to 7. The pyruvate preparation is used for daily management of asthma patients, the purpose of inhibiting asthma is achieved by controlling increase of the number of inflammatory cells such as eosinophilic granulocytes and reducing inflammatory reaction, the effect of the pyruvate preparation is close to that of similar hormone medicine dexamethasone, and the effect of the pyruvate preparation is improved while the treatment purpose is achieved. The dependence and side effects of patients on hormone drugs are reduced.

Provided are an anti-CD3 antibody or an antigen-binding fragment thereof, and a use thereof. The anti-CD3 antibody comprises: heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 1-3, 7-8 and 74-86 or a conservatively modified form thereof, and / or the light chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 4-6, 9 and 87-92 or a conservatively modified form thereof. The provided anti-CD3 antibody or antigen-binding fragment thereof can bind to human CD3 protein and reduce the production of pro-inflammatory cytokines, and a bispecific antibody constructed using same has high PBMC tumor-killing activity and weak promotion of the secretion of pro-inflammatory cytokines. A pharmaceutical composition prepared using the anti-CD3 antibody or the antigen-binding fragment thereof or a multi-specific antibody thereof has better safety, and has value for clinical applications and drug development.

The invention belongs to the field of drug preparation, and particularly relates to a preparation method and application of a drug delivery system based on hollow mesoporous polydopamine nanoparticles. The drug delivery system comprises hollow mesoporous polydopamine nanoparticles, a drug loaded inside and / or outside the hollow mesoporous polydopamine nanoparticles, and pectin wrapping the hollow mesoporous polydopamine nanoparticles, the medicine is a medicine with a nerve protection effect and an acetylcholin esterase inhibitor. The drug delivery system can reduce proinflammatory cytokines, regulate functions of target immune cells, synergistically reduce necrosis of neurons in intestinal tracts and induce neural crest stem cells in the intestinal tracts to be differentiated into neurons.

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The purpose of the present invention is to provide a novel therapeutic agent or prophylactic agent for dry eye, a therapeutic agent or prophylactic agent for a graft-versus-host disease, a corneal epithelial wound healing promoter, an inflammatory cell inhibitor that infiltrates the cornea, a tear fluid amount retaining agent, a corneal epithelial disorder inhibitor, a cell proliferation marker-positive cell inhibitor, and an inhibitor of lymphocyte differentiation into effector T cells. The present invention provides the following, each of which contains, as an active ingredient, a substance derived from a culture supernatant of stem cells: a therapeutic agent or prophylactic agent for dry eye; a therapeutic agent or prophylactic agent for a graft-versus-host disease; a corneal epithelial wound healing promoter; an inflammatory cell inhibitor infiltrating into the cornea; a tear fluid amount retaining agent; a corneal epithelial disorder inhibitor; a cell proliferation marker-positive cell inhibitor; or an inhibitor of lymphocyte differentiation into effector T cells.

The invention belongs to the technical field of targeting exosome preparation, and particularly relates to a targeting modification method of a rose exosome, a hyaluronic acid modified rose exosome and application of the hyaluronic acid modified rose exosome. The method comprises the following steps: dissolving hyaluronic acid in a rose exosome, adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and N-hydroxysuccinimide, carrying out a reaction for 8-16 h, carrying out centrifugation, and carrying out resuspension precipitation so as to obtain a hyaluronic acid modified rose exosome; the volume mass ratio of the hyaluronic acid to the rose exosome solution is 1 mg: (0.5-1) ml, and the hyaluronic acid, the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and the N-hydroxysuccinimide are in an equal molar ratio. The characteristic that hyaluronic acid is highly compatible with an inflammatory cell CD44 receptor is utilized, the targeting property of the rose exosome to inflammatory cells is enhanced, and the utilization rate and the anti-inflammatory effect of the rose exosome are further improved.

The invention belongs to the technical field of biological medicine, and particularly relates to application of polypeptide in treatment of psoriasis. The amino acid sequence of the polypeptide provided by the invention is SEQ ID NO.1, so that the spleen-body ratio of a psoriasis mouse can be effectively reduced, and the inflammation level in the body can be reduced; the epidermal thickness of psoriasis mice and inflammatory factors in skin lesion tissues can be remarkably reduced, keratinocyte proliferation is reduced, and inflammatory factors released by inflammatory cells recruited to skin lesion positions are reduced. The polypeptide provided by the invention shows certain advantages in the aspects of relieving inflammatory response, promoting tissue repair and the like when being used for treating psoriasis. The invention provides a new method and means for treating psoriasis, and promotes the progress and development of medicine.

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention discloses an application of core proteoglycan or a coding gene thereof as a target spot in preparation of psoriasis treatment drugs, and a series of experiments prove that DCN can effectively protect mouse psoriasis-like dermatitis induced by imiquimod, improve skin scale, erythema, thickening and epidermal abnormal differentiation, enhance the barrier function of skin, improve the curative effect of psoriasis, and improve the curative effect of psoriasis. A large amount of infiltration of inflammatory cells is reduced, and a certain anti-inflammatory effect is achieved. Experimental research shows that the DCN has an obvious drug effect on a psoriasis model, is safe and efficient, has no side effect, is simple in production process and has the potential of realizing medical transformation. And the potential application value of the DCN on other various skin inflammatory diseases can be expanded.

The invention discloses a grape seed source anti-inflammatory peptide, and belongs to the technical field of biological medicine. The amino acid sequence of the anti-inflammatory peptide is selected from any one of WGF, SHFGF, EGPFF, WAPR, SFYRAF, HFAFL, PGRF or FDSF. A BPS-induced RAW 264.7 mouse mononuclear macrophage inflammation model is established, and the eight synthetic peptides are found to significantly reduce the content level of NO in inflammatory cells and have an inhibition effect on secretion of inflammatory factors TNF-alpha and IL-6. A qRT-PCR (quantitative reverse transcription-polymerase chain reaction) experiment shows that the synthetic peptide can inhibit expression of mRNA (messenger Ribonucleic Acid) of p65, Tnf alpha, Il6, Il1b and Nos2, and can play an anti-inflammatory role by regulating and controlling an NF-kappa B signal channel. According to the method, the high-activity anti-inflammatory peptide is screened from the wine brewing byproduct grape seeds for the first time, and green and high-value utilization of the grape processing byproduct is realized.

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising selexipag or a pharmaceutically acceptable salt thereof as an active ingredient. Selexipag inhibits the expression and production of pro-inflammatory or inflammatory cytokines in brain tissue, inhibits the activity of microglia or astrocytes, inhibits NLRP3 inflammasome activity and CDK6 expression, reduces amyloid plaques, increases the expression of the amyloid beta-degrading enzyme IDE, and inhibits the hyperphosphorylation of tau protein and the expression of tau kinase, and thus can be effectively used as a novel therapeutic agent for the prevention or treatment of degenerative brain diseases, cognitive disorders, learning disabilities, or memory disorders.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

A composition for the surface treatment of a polymer material includes a hyperbranched polyglycerol comprising a glycidol-derived repeating unit and an unsubstituted or substituted acrylate group at least at one end thereof. The composition has the effect of suppressing fibrosis, thrombus formation, or inflammatory cell adsorption by preventing proteins from being adsorbed to the surface of a polymer material that is surface-treated with the composition or an in-vivo implantation material including a polymer material.

The invention relates to pediococcus acidilactici PA27 capable of degrading alcohol and improving alcoholic nerve injury and application of the pediococcus acidilactici PA27, the pediococcus acidilactici PA27 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.31922. The pediococcus acidilactici PA27 can degrade alcohol and improve alcoholic nerve injury. The pediococcus acidilactici PA27 separated and screened by the invention can grow and propagate in an alcohol-containing culture medium, can degrade alcohol and can generate ethanol dehydrogenase and acetaldehyde dehydrogenase; the polypeptide can be used for constructing a blood-brain barrier and reducing the damage of alcohol to central nervous cells; the traditional Chinese medicine composition can reduce the expression of inflammatory cytokines TNF-alpha, inhibit the activation of astrocytes, promote the expression of brain-derived neurotrophic factors BDNF, regulate the release of alcohol-induced astrocyte neurotransmitters and improve alcoholic nerve injury.

The invention provides a traditional Chinese medicine compound for treating sicca syndrome and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compounds. The traditional Chinese medicine compound provided by the invention has the effects of eliminating dampness and heat, removing blood stasis and promoting salivation, can safely and effectively treat sicca syndrome by improving functions of exocrine glands and regulating immunity, belongs to a pure traditional Chinese medicine preparation, and has no toxic or side effect. The traditional Chinese medicine compound is proved to be capable of remarkably relieving the sicca syndrome, relieving dry mouth and eye symptoms of a patient, relieving fatigue, regulating and controlling a plurality of signals taking RAGE / TLR4 as a core, inhibiting excessive activation of an HMGB1-RAGE / TLR4-NF-kappa B pro-inflammatory pathway from gene and protein levels, inhibiting generation of pro-inflammatory cytokines, reducing inflammatory response and improving the immunity of the patient. The effect of treating the sicca syndrome is achieved. By acting on STAT3 phosphorylation, Tfh proliferation is inhibited, IL-21 secretion is reduced, humoral immune disorder is relieved, and the sicca syndrome is treated, so that the condition of the sicca syndrome is relieved, and the prognosis of the sicca syndrome is improved.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention relates to the technical field of biological materials, in particular to a cyclic peptide derivative and a preparation method and application thereof. The cyclopeptide derivative provided by the invention simultaneously comprises a hydrophobic cyclopeptide structure and a hydrophilic pantothenic acid structure which are combined through a covalent ester bond; due to the structure, excellent stability is achieved, and the problems that pantothenic acid is unstable and irritant are effectively solved; after entering the skin, the derivative can be hydrolyzed into pantothenic acid under the action of esterase, and can play a role without oxidative conversion of panthenol. Secondly, the cyclic peptide derivative disclosed by the invention has good biological safety; in an inflammatory cell model, the derivative can more effectively reduce expression of inflammatory factors, and antioxidant activity research shows that the derivative has a strong free radical inhibition effect and can exert excellent anti-inflammatory and antioxidant effects.

The invention discloses a quantitative index determination method and device based on a hepatitis pathology image, equipment, a medium and a product, and relates to the field of medical pathology image artificial intelligence analysis, and the method comprises the steps: obtaining an image of a liver puncture pathology section; according to the image of the hepatic puncture pathological section, performing feature extraction by using a multi-stage model cascade architecture to obtain a pathological feature result; the multi-stage model cascade architecture comprises an improved VM-UNet segmentation model and a VM classification model based on FEM enhancement, and the VM classification model is connected with the improved VM-UNet segmentation model; the pathological feature result comprises the expansion level of the manifold area, the necrosis type of the manifold area and the inflammatory cell information of the manifold area; and calculating a quantitative index according to the pathological feature result. According to the invention, the accuracy, objectivity, consistency and repeatability of identification can be improved.

The invention discloses probiotics with an effect of improving vaginitis and a composite microecological preparation and application of the probiotics. The probiotics are characterized by comprising at least one of a plant lactobacillus 22-9 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.33867, a plant lactobacillus XA-9 strain with the preservation number of CGMCC No.33868 and a plant lactobacillus pentosus B-1-35 strain with the preservation number of CGMCC No.33870, the preparation method comprises the following steps: inoculating a lactic acid bacteria starter, which is prepared by mixing lactic acid bacteria cultures of plant lactobacillus 22-9, plant lactobacillus XA-9 and plant lactobacillus pentosus B-1-35 according to a volume ratio of 2: 1: 3, into a fermentation culture medium according to a volume ratio of 1-5%, so as to prepare the probiotic compound microecological preparation. The number of inflammatory cells in the vagina is reduced, and the levels of inflammatory factors IL-1beta, IL-6 and TNF-alpha in serum are reduced.

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The invention discloses an image recognition analysis method and system for heart macrophage inflammation regulation and control, and relates to the technical field of macrophage inflammation regulation and control recognition, and the method comprises the following steps: observing and obtaining a cell image through a fluorescence microscope, and preprocessing the cell image to obtain a preprocessed image; constructing a cell recognition deep learning model, and training the cell recognition deep learning model by extracting fluorescence features of macrophages and gray features of inflammatory cells; carrying out statistics on macrophages and inflammatory cells in the inflammation area, and outputting a regulation and control inspection result; the method is used for solving the problem that the judgment of doctors on the condition of cardiac inflammation is easily affected due to insufficient recognition accuracy of macrophages and inflammatory cells in the existing macrophage inflammation regulation and control recognition technology.

The invention discloses an application of a training immune agonist in preparation of a drug for sensitizing radiotherapy treatment of tumors, and researches show that the training immune agonist significantly activates immune response of a body by promoting expression of inflammatory cytokines, enhancing phagocytic ability of macrophages, recruiting immune cells and amplifying an immune activation effect, so that the immune response of the body is enhanced. The sensitivity of tumor cells to radiotherapy is improved, and a dual mechanism of'radiotherapy sensitization-immune synergy 'is formed, so that the bottleneck of the traditional radiotherapy curative effect is broken through, the local control rate of radiotherapy is improved, and the recurrence risk is reduced. Experiments prove that the training immune agonist combined with radiotherapy has a remarkable treatment effect on various highly invasive tumors (such as brain glioma and lung cancer brain metastasis) and common malignant tumors (such as colon cancer and lung cancer), and shows wide applicability. The invention provides a new combined therapy direction for tumor treatment, is expected to improve the prognosis of patients, prolong the lifetime and improve the life quality, and has important clinical transformation value.

The invention belongs to the technical field of medicines, and particularly relates to application of hordenine in preparation of a medicine for treating and relieving tissue damage. It is found that hordenine shows the effect of relieving immunological liver injury and spleen injury on an animal model, therefore, the application of hordenine to preparation of the medicine for treating and relieving tissue injury is provided, hordenine shows a remarkable curative effect, symptoms of immunological liver injury and pathological injury of spleen and thymus can be effectively relieved, and the hordenine can be used for preparing the medicine for treating and relieving tissue injury. The conditions include abnormal liver cell morphology, inflammatory cell tissue infiltration, pathological injuries such as extravasated blood and necrosis, cell apoptosis and the like. Animal experiments show that no obvious toxic reaction or side effect is observed while the hordenine is used for relieving immunological liver injury, spleen injury and thymus injury.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.